A study explores how cationic fusogenic liposomes temporarily modify membrane properties during fusion, offering new insights for drug delivery applications.

The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma.

GLP-1 and GLP-2 coinfusion resulted in net increased lipid absorption and an increase in TRL-TG and apoB48. However, prolonged (120-min) coinfusion of GLP-1 and GLP-2 decreased postprandial lipemia.

The researchers then packaged the AHPC-modified tumor proteins into tiny lipid (fat molecule) nanoparticles, specifically designed to home in on lymph nodes, where most antigen-presenting cells ...